Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DBI-001 in Tinea Pedis
NCT04152226Phase 2Completed
- Sponsor
- DermBiont, Inc.
- Start
- Feb 2019
- Primary completion
- Apr 2019
- Countries
- 1
01
Overview
Phase 2, open-label trial in tinea pedis (3 cohorts), sponsored by DermBiont, Inc. Primary endpoint: Safety Evaluation at 28 days. Started Feb 2019; status: completed.
02
Conditions
tinea pedis
Beyond the preview
Go deeper on NCT04152226.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04152226.